Vision loss after chemotherapy: an irinotecan-induced retinopathy. (May 2019)

• Record Type: Journal Article
• Authors: Boilève, Alice; Jozwiak, Mathieu; Malka, David; Boige, Valérie; Le Roy, Florence; Paques, Michel; Ducreux, Michel
• Is Part Of: European journal of cancer. Volume 112(2019)
• Page Start: 80
• Page End: 82
• Publication Date: 2019-05
• Subjects: Irinotecan -- Vision loss -- Toxicity -- Photoreceptors -- Retinopathy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2019.02.015
• Languages: English
• ISSNs: 0959-8049

Abstract

Highlights: Irinotecan is a topoisomerase-I inhibitor widely used for gastrointestinal tumours. Vision loss has never been reported after irinotecan infusion. Irinotecan-induced retinopathy has never been reported so far. This toxicity is characterised by a diffuse loss of photoreceptors' outer segments. Further studies are required to better characterise irinotecan-induced retinopathy.